196811-66-2

Basic information

• Product Name: 4-THIOCARBAMOYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 4-THIOCARBAMOYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;4-(tert-Butoxycarbonyl)piperazine-1-thiocarboxamide;tert-butyl 4-carbamothioylpiperazine-1-carboxylate;1-Boc-4-CarbaMothioylpiperazine;1-Piperazinecarboxylic acid, 4-(aMinothioxoMethyl)-, 1,1-diMethylethyl ester;1-Piperazinecarboxylic ac...;4-(tert-Butoxycarbonyl)piperazine-1-
• CAS NO: 196811-66-2
• Molecular Formula: C₁₀H₁₉N₃O₂S
• Molecular Weight: 245.34
• Mol File: 196811-66-2.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 354.7°C at 760 mmHg
• Flash Point: 168.3°C
• Appearance: /
• Density: 1.214g/cm³
• Vapor Pressure: 3.29E-05mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 16.15±0.20(Predicted)
• CAS DataBase Reference: 4-THIOCARBAMOYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-THIOCARBAMOYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(196811-66-2)
• EPA Substance Registry System: 4-THIOCARBAMOYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(196811-66-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 196811-66-2(Hazardous Substances Data)

Usage

General Description

4-Thiocarbamoyl-Piperazine-1-Carboxylic acid tert-butyl ester is a chemical compound featuring functional groups like thiocarbamoyl, piperazine, carboxylic acid, and tert-butyl ester. 4-THIOCARBAMOYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER has not been largely studied, so its specific applications are not well-defined. However, based on its structure, it might be useful in various scientific and industrial contexts. These could include potential use in pharmaceuticals, as many piperazine derivatives are central nervous system stimulants or have antimicrobial effects. It might also be useful as a reagent or intermediate in organic synthesis due to its functional groups, which make it highly reactive and versatile. However, without more specific information, these potential applications remain largely speculative.

InChI:InChI=1/C10H19N3O2S/c1-10(2,3)15-9(14)13-6-4-12(5-7-13)8(11)16/h4-7H2,1-3H3,(H2,11,16)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1018148-64-5 tert-butyl 4-(benzoylcarbamothioyl)piperazine-1-carboxylate 
• 88681-68-9 di(1H-imidazol-2-yl)methanethione 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 6160-65-2 1,1'-Thiocarbonyldiimidazole 

Downstream Products

• 668484-34-2 C₁₈H₂₂BrN₃O₂S 
• 294622-59-6 4-[4-(4-carboxy-phenyl)-thiazol-2-yl]-piperazine-1-carboxylic acid tert-butyl ester 
• 69389-14-6 4-phenyl-2-(piperazin-1-yl)thiazole 
• 867065-53-0 4-(4-ethoxycarbonylthiazol-2-yl)piperazine-1-carboxylic acid tert-butyl ester 
• 887624-04-6 tert-butyl 4-(4-phenylthiazol-2-yl)piperazine-1-carboxylate 
• 105653-53-0 ethyl 2-(piperazin-1-yl)thiazole-4-carboxylate hydrochloride 

Relevant articles and documents

Efficient Synthesis of Benzothiazinone Analogues with Activity against Intracellular Mycobacterium tuberculosis

8-Nitrobenzothiazinones (BTZs) are a promising class of antimycobacterial agents currently under investigation in clinical trials. Starting from thiourea derivatives, a new synthetic pathway to BTZs was established. It allows the formation of the thiazinone ring system in one synthetic step and is applicable for preparation of a wide variety of BTZ analogues. The synthetic procedure furthermore facilitates the replacement of the sulphur atom in the thiazinone ring system by oxygen or nitrogen to afford the analogous benzoxazinone and quinazolinone systems. 36 BTZ analogues were prepared and tested in luminescence-based assays for in vitro activity against Mycobacterium tuberculosis (Mtb) using the microdilution broth method and a high-throughput macrophage infection assay.

ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES

The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and in particular as glycosidase inhibitors.

SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE

Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).